Drafting Penicillium oxalicum calcineurin-CrzA pathway by combining the analysis of phenotype, transcriptome, and endogenous protein-protein interactions

2021 ◽  
pp. 103652
Author(s):  
Kaili Zhao ◽  
Zhongjiao Liu ◽  
Mengxue Li ◽  
Yueyan Hu ◽  
Ling Yang ◽  
...  
Keyword(s):  
Protein Interactions ◽  
Penicillium Oxalicum ◽  
Protein Protein Interactions ◽  
Endogenous Protein

scholarly journals EndoBind detects endogenous protein-protein interactions in real time

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Anke Bill ◽  
Sheryll Espinola ◽  
Daniel Guthy ◽  
Jacob R. Haling ◽  
Mylene Lanter ◽  
...  
Keyword(s):  
Real Time ◽  
High Throughput ◽  
Protein Interactions ◽  
Continuous Monitoring ◽  
Protein Protein Interactions ◽  
Dimer Formation ◽  
Endogenous Protein ◽  
Extended Duration ◽  
Substrate Addition

AbstractWe present two high-throughput compatible methods to detect the interaction of ectopically expressed (RT-Bind) or endogenously tagged (EndoBind) proteins of interest. Both approaches provide temporal evaluation of dimer formation over an extended duration. Using examples of the Nrf2-KEAP1 and the CRAF-KRAS-G12V interaction, we demonstrate that our method allows for the detection of signal for more than 2 days after substrate addition, allowing for continuous monitoring of endogenous protein-protein interactions in real time.

scholarly journals A Comprehensive Review on Current Advances in Peptide Drug Development and Design

2019 ◽  
Vol 20 (10) ◽  
pp. 2383 ◽  
Author(s):  
Andy Chi-Lung Lee ◽  
Janelle Louise Harris ◽  
Kum Kum Khanna ◽  
Ji-Hong Hong
Keyword(s):  
Drug Development ◽  
Binding Affinity ◽  
Protein Interactions ◽  
Binding Sites ◽  
Drug Targets ◽  
Peptide Drug ◽  
Protein Protein Interactions ◽  
Cellular Functions ◽  
Endogenous Protein ◽  
Binding Interfaces

Protein–protein interactions (PPIs) execute many fundamental cellular functions and have served as prime drug targets over the last two decades. Interfering intracellular PPIs with small molecules has been extremely difficult for larger or flat binding sites, as antibodies cannot cross the cell membrane to reach such target sites. In recent years, peptides smaller size and balance of conformational rigidity and flexibility have made them promising candidates for targeting challenging binding interfaces with satisfactory binding affinity and specificity. Deciphering and characterizing peptide–protein recognition mechanisms is thus central for the invention of peptide-based strategies to interfere with endogenous protein interactions, or improvement of the binding affinity and specificity of existing approaches. Importantly, a variety of computation-aided rational designs for peptide therapeutics have been developed, which aim to deliver comprehensive docking for peptide–protein interaction interfaces. Over 60 peptides have been approved and administrated globally in clinics. Despite this, advances in various docking models are only on the merge of making their contribution to peptide drug development. In this review, we provide (i) a holistic overview of peptide drug development and the fundamental technologies utilized to date, and (ii) an updated review on key developments of computational modeling of peptide–protein interactions (PepPIs) with an aim to assist experimental biologists exploit suitable docking methods to advance peptide interfering strategies against PPIs.

Using an in Situ Proximity Ligation Assay to Systematically Profile Endogenous Protein–Protein Interactions in a Pathway Network

2014 ◽  
Vol 13 (12) ◽  
pp. 5339-5346 ◽  
Author(s):  
Tzu-Chi Chen ◽  
Kuan-Ting Lin ◽  
Chun-Houh Chen ◽  
Sheng-An Lee ◽  
Pei-Ying Lee ◽  
...  
Keyword(s):  
Protein Interactions ◽  
Proximity Ligation Assay ◽  
Protein Protein Interactions ◽  
Pathway Network ◽  
Proximity Ligation ◽  
Endogenous Protein

scholarly journals Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators

2021 ◽  
Vol 9 ◽  
Author(s):  
Keith M. Olson ◽  
John R. Traynor ◽  
Andrew Alt
Keyword(s):  
Small Molecules ◽  
Protein Interactions ◽  
Drug Targets ◽  
Vital Role ◽  
Allosteric Modulators ◽  
Protein Protein Interactions ◽  
Good Tolerability ◽  
Endogenous Protein ◽  
Biased Signaling ◽  
G Protein Coupled

Allosteric modulators (AMs) of G-protein coupled receptors (GPCRs) are desirable drug targets because they can produce fewer on-target side effects, improved selectivity, and better biological specificity (e.g., biased signaling or probe dependence) than orthosteric drugs. An underappreciated source for identifying AM leads are peptides and proteins—many of which were evolutionarily selected as AMs—derived from endogenous protein-protein interactions (e.g., transducer/accessory proteins), intramolecular receptor contacts (e.g., pepducins or extracellular domains), endogenous peptides, and exogenous libraries (e.g., nanobodies or conotoxins). Peptides offer distinct advantages over small molecules, including high affinity, good tolerability, and good bioactivity, and specific disadvantages, including relatively poor metabolic stability and bioavailability. Peptidomimetics are molecules that combine the advantages of both peptides and small molecules by mimicking the peptide’s chemical features responsible for bioactivity while improving its druggability. This review 1) discusses sources and strategies to identify peptide/peptidomimetic AMs, 2) overviews strategies to convert a peptide lead into more drug-like “peptidomimetic,” and 3) critically analyzes the advantages, disadvantages, and future directions of peptidomimetic AMs. While small molecules will and should play a vital role in AM drug discovery, peptidomimetics can complement and even exceed the advantages of small molecules, depending on the target, site, lead, and associated factors.

Protein-protein interactions of the p53 family with the Bcl-2 family in hepatocellular carcinoma

2011 ◽  
Vol 49 (08) ◽  
Author(s):  
LC König ◽  
M Meinhard ◽  
C Sandig ◽  
MH Bender ◽  
A Lovas ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Protein Interactions ◽  
Protein Protein Interactions ◽  
P53 Family

Partial Purification of a Specific Plasminogen Activator from Porcine Parotid Glands

1974 ◽  
Vol 31 (03) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Cartwright
Keyword(s):  
Nucleic Acid ◽  
Salivary Glands ◽  
Plasminogen Activator ◽  
Protein Interactions ◽  
Partial Purification ◽  
Protein Protein Interactions ◽  
Parotid Glands ◽  
Two Stage ◽  
Preliminary Characterization ◽  
Specific Inhibitors

SummaryA method is described for the extraction with buffers of near physiological pH of a plasminogen activator from porcine salivary glands. Substantial purification of the activator was achieved although this was to some extent complicated by concomitant extraction of nucleic acid from the glands. Preliminary characterization experiments using specific inhibitors suggested that the activator functioned by a similar mechanism to that proposed for urokinase, but with some important kinetic differences in two-stage assay systems. The lack of reactivity of the pig gland enzyme in these systems might be related to the tendency to protein-protein interactions observed with this material.

Target-Templated de novo Design of Macrocyclic D-/L-Peptides: Inhibitors of the PD-1/PD-L1 Interaction

2020 ◽  
Author(s):  
Salvador Guardiola ◽  
Monica Varese ◽  
Xavier Roig ◽  
Jesús Garcia ◽  
Ernest Giralt
Keyword(s):  
Protein Interactions ◽  
Cyclic Peptides ◽  
General Framework ◽  
Large Scale ◽  
De Novo ◽  
Inhibitory Effect ◽  
Original Text ◽  
Protein Protein Interactions ◽  
Retraction Notice ◽  
Pharmaceutical Properties

<p>NOTE: This preprint has been retracted by consensus from all authors. See the retraction notice in place above; the original text can be found under "Version 1", accessible from the version selector above.</p><p><br></p><p>------------------------------------------------------------------------</p><p><br></p><p>Peptides, together with antibodies, are among the most potent biochemical tools to modulate challenging protein-protein interactions. However, current structure-based methods are largely limited to natural peptides and are not suitable for designing target-specific binders with improved pharmaceutical properties, such as macrocyclic peptides. Here we report a general framework that leverages the computational power of Rosetta for large-scale backbone sampling and energy scoring, followed by side-chain composition, to design heterochiral cyclic peptides that bind to a protein surface of interest. To showcase the applicability of our approach, we identified two peptides (PD-<i>i</i>3 and PD-<i>i</i>6) that target PD-1, a key immune checkpoint, and work as protein ligand decoys. A comprehensive biophysical evaluation confirmed their binding mechanism to PD-1 and their inhibitory effect on the PD-1/PD-L1 interaction. Finally, elucidation of their solution structures by NMR served as validation of our <i>de novo </i>design approach. We anticipate that our results will provide a general framework for designing target-specific drug-like peptides.<i></i></p>

Sign in / Sign up

Export Citation Format

Share Document